Clinical Trials Browser

INDUSTRY × MORAb-202 × Clear all

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05577715 2025-09-04

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Phase 2 Terminated

31 enrolled 12 charts

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT03386942 2022-11-28

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

Phase 1 Completed

Pyogenic arthritis, pyoderma gangrenosum, and acne, Carcinoma, Non-Small-Cell Lung